SCHEMBL25097040

SCHEMBL25097040

COc1cnc2c(Br)ccc(C(=O)O)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.46
POLB P06746 1/20 0.46
HSD17B10 Q99714 1/20 0.40
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
SIRT6 Q8N6T7 1/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
PABPC1 P11940 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
NNMT P40261 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CHEK1 O14757 1/20 0.33
NTRK2 Q16620 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MAPT P10636 1/20 0.33
EPRS1 P07814 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25095962 0.94 TDP1 (0.46) TDP1POLBHSD17B10LCKFYN
SCHEMBL30217882 0.94 TDP1 (0.46) TDP1POLBHSD17B10LCKFYN
SCHEMBL25097060 0.87 L3MBTL1 (0.43) TDP1POLBMEN1KMT2AALDH1A1
SCHEMBL14486349 0.82 NQO2 (0.44) SIRT6MEN1KMT2AALDH1A1KDM4E
SCHEMBL30217762 0.81 L3MBTL1 (0.43) TDP1POLBMEN1KMT2AALDH1A1
SCHEMBL25095959 0.81 L3MBTL1 (0.43) TDP1POLBMEN1KMT2AALDH1A1
SCHEMBL30217793 0.80 RXFP1 (0.39) MEN1KMT2AALDH1A1HPGDRXFP1
SCHEMBL25096885 0.80 RXFP1 (0.39) MEN1KMT2AALDH1A1HPGDRXFP1
SCHEMBL30753385 0.75 ALDH1A1 (0.53) TDP1POLBHSD17B10MEN1KMT2A
SCHEMBL25096316 0.74 RXFP1 (0.39) MEN1KMT2AALDH1A1HPGDRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-12-12 US disclosed
EP-4395891-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
CN-118234724-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-06-21 CN disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 TDP1 406/4885POLB 289/4885HSD17B10 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.